Peripheral blood immune cells and prognosis of patients undergoing radical resection for colorectal cancer
Conditions
Interventions
Lidocaine group (Group L:Before induction, lidocaine was given with a load of 1.5mg/kg within 15 minutes, and the maintenance period was intravenously pumped at a rate of 1.5mg/kg/h until the end of t
Control group (Group C):According to the same lidocaine concentration calculation as the group L, the same volume of saline was given before induction, and the saline was pumped at the same volume rat
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences Shanxi Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: ASA classification :?-?; 18-65 years old; Patients undergoing elective radical resection of colorectal cancer.
Exclusion criteria
Exclusion criteria: BMI=30; Low body weight (<45kg); History of other operations; Allergic to lidocaine; History of chronic pain; History of epilepsy; History of heart disease (coronary heart disease, valvular heart disease, arrhythmia), preoperative cardiac insufficiency; Liver disease; Preoperative hepatic and renal insufficiency Complicated with other malignant tumors; Preoperative co-infection; Preoperative anticancer therapy (focusing on therapies that have a significant effect on immunity); Preoperative history of antibiotics, anti-inflammatory drugs, painkillers and hormones; Metastases of other organs have occurred; Preoperative complications of gastrointestinal obstruction or perforation; Preoperative psychosis; Preoperative internal environment disorders (e.g., hypokalemia, acidosis); Preoperatively combined with hypoxemia or type I or II respiratory failure; Preoperatively combined with hypoalbuminemia; Preoperatively associated with abnormal coagulation function; Preoperative complication of inflammatory bowel and other immune diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference between the proportion of peripheral venous NK cells measured by flow cytometry immediately after surgery and the proportion measured within 1 hour before surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse event;Flow cytometry results;Field activity time;Intestinal exhaust time;QoR-15 rating;MoCA scores;3D-CAM scores;VAS scores;hospital stays;Total hospital expenditure;Relapse or not;death rate and the time and cause of death;Whether to be hospitalized again and the reason for hospitalization;High throughput data of peripheral venous blood mononuclear cell transcriptome;Peripheral venous blood cell cluster proteome high throughput data;High throughput data for peripheral venous serum proteome;Peripheral venous blood cytokine concentration; | — |
Countries
China
Contacts
Public ContactShouyuan Tian
Cancer Hospital, Chinese Academy of Medical Sciences, Shanxi Hospital, Cancer Hospital Affiliated to Shanxi Medical University
Outcome results
None listed